Edwards Lifesciences (Irvine, California) investors seemed to breathe a collective sigh of relief Monday afternoon when the company released data at the Society of Thoracic Surgeons (STS; Chicago) that restored confidence in the transapical approach (TA) for delivering the company's Sapien transcatheter heart valve to high-risk surgical patients with severe aortic stenosis. These patients were treated during the continued access period (CAP) of Cohort A of the PARTNER trial.